Asle Hesla

Om mig
Publikationer
CV
Populärvetenskap och samverkan

Forskningsbeskrivning

Forskargrupp: Ortopedi, Institutionen för molekylär medicin och kirurgi [1]
[1] https://ki.se/mmk/ortopedi

Artiklar

Article: MODERN PATHOLOGY. 2021;34(11):2020-2027

TERT promoter mutation is an objective clinical marker for disease progression in chondrosarcoma.

Zhang Y; Chen Y; Yang C; Seger N; Hesla AC; Tsagkozis P; Larsson O; Lin Y; Haglund F
Article: MOLECULAR ONCOLOGY. 2020;14(5):1101-1117

Transcriptome profiling of Ewing sarcomas - treatment resistance pathways and IGF-dependency.

Chen Y; Hesla AC; Lin Y; Ghaderi M; Liu M; Yang C; Zhang Y; Tsagkozis P; Larsson O; Haglund F
Article: BRITISH JOURNAL OF CANCER. 2020;122(8):1242-1249

Subsequent primary neoplasms among bone sarcoma survivors; increased risks remain after 30 years of follow-up and in the latest treatment era, a nationwide population-based study.

Hesla AC; Discacciati A; Tsagkozis P; Smedby KE
Article: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2019;68(6):927-936

An immunosuppressive macrophage profile attenuates the prognostic impact of CD20-positive B cells in human soft tissue sarcoma.

Tsagozis P; Augsten M; Zhang Y; Li T; Hesla A; Bergh J; Haglund F; Tobin NP; Ehnman M
Article: JOURNAL OF BONE ONCOLOGY. 2019;14:100216

Ewing sarcoma of the mobile spine; predictive factors for survival, neurological function and local control. A Scandinavian sarcoma group study with a mean follow-up of 12 years.

Hesla AC; Bruland ØS; Jebsen N; Styring E; Eriksson S; Tsagozis P
Article: BRITISH JOURNAL OF CANCER. 2019;120(4):435-443

Drug sensitivity testing on patient-derived sarcoma cells predicts patient response to treatment and identifies c-Sarc inhibitors as active drugs for translocation sarcomas.

Brodin BA; Wennerberg K; Lidbrink E; Brosjö O; Potdar S; Wilson JN; Ma L; Moens LN; Hesla A; Porovic E; Bernhardsson E; Papakonstantinou A; Bauer H; Tsagkozis P; von Sivers K; Wejde J; Östling P; Kallioniemi O; Stragliotto CL
Article: MODERN PATHOLOGY. 2018;31(12):1834-1841

hTERT promoter mutations in chondrosarcomas associate with progression and disease-related mortality.

Lin Y; Seger N; Chen Y; Hesla AC; Wejde J; Ghaderi M; Tsagkozis P; Larsson O; Haglund F
Article: JOURNAL OF CLINICAL PATHOLOGY. 2018;71(9):832-839

Telomerase promoter mutations and copy number alterations in solitary fibrous tumours.

Lin Y; Seger N; Tsagkozis P; Hesla AC; Ghaderi M; Chen Y; Ehnman M; Warsito D; Wejde J; Larsson O; Haglund F
Article: JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME. 2016;98(3):199-210

Improved Prognosis for Patients with Ewing Sarcoma in the Sacrum Compared with the Innominate Bones: The Scandinavian Sarcoma Group Experience.

Hesla AC; Tsagozis P; Jebsen N; Zaikova O; Bauer H; Brosjö O
Article: ACTA ORTHOPAEDICA. 2013;84(5):502-505

Sclerotherapy with polidocanol for treatment of aneurysmal bone cysts.

Brosjö O; Pechon P; Hesla A; Tsagozis P; Bauer H

Alla övriga publikationer

Review: CANCERS. 2021;13(6):1202

Current Status of Management and Outcome for Patients with Ewing Sarcoma.

Hesla AC; Papakonstantinou A; Tsagkozis P
Thesis / dissertation: 2020

Ewing sarcoma : treatment, prognosis and late effects

Hesla, Asle Charles
Corrigendum: JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME. 2016;98(7):e29

Erratum.

Anställningar

Anknuten till Forskning, Molekylär medicin och kirurgi, Karolinska Institutet, 2021-2024

Examina och utbildning

Medicine Doktorsexamen, Institutionen för molekylär medicin och kirurgi, Karolinska Institutet, 2020

Forskningsbeskrivning

Artiklar

Alla övriga publikationer

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI